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Summary 
Models of T  cell recognition  suggest that  amino  acid residues in the CDR3 region of the T 
cell receptor (TCR) ol or B chain directly contact the major histocompatibility complex-bound 
peptide, and thus are crucial for providing peptide specificity.  T  cells derived from B10.PL or 
PL/J mice of H-2  u haplotype, use only D~/2 and J~2 gene segments in the recognition of the 
dominant determinant,  Acl-9/A u, of myelin basic protein (MBP). New Zealand White (NZW) 
mice, with identical class II H-2  u genes (I-A and I-E),  carry an 8.8-kb deletion in their TCR 
B chain locus encompassing D~2 and J~2 gene segments. How does this deletion of the crucial 
DB2-J~2  region  in  NZW  mice influence  specific  responses  to  Acl-9/A u as well  as to  other 
known A u or E u determinants  of MBP? We found that these mice respond very poorly to the 
dominant Acl-9/A u and to the subdominant 31-50/E u determinant in in vitro proliferation assays 
as well as in their in vivo capacity to induce experimental autoimmune encephalomyelitis. This 
loss of response is apparently owing to the absence of high avidity TCRs with essential CDR3 
residues contributed by D/32 or J/32 gene segments. These data reveal constraints in the recognition 
of certain antigenic structures, and further support a TCR-recognition model in which CDtL3 
residues of the TCR c~ and ~ chains constitute the antigenic peptide-binding sites on the TCR 
molecule. Implications for autoimmune manifestations contributed by NZW genes in (NZB x 
NZW)F1 disease  are  also discussed. 
T  cells recognize peptide-MHC complexes using specific 
TCR heterodimers (1). In most peripheral T  cells, this 
recognition is mediated by the TCR-CD3 complex, consisting 
of invariant CD3 polypeptides (2) in association with poly- 
morphic ol and/3 chains that provide specificity for the rec- 
ognition of Ag-MHC. As with immunoglobulins,  receptor 
diversity is generated using somatic recombination of vari- 
able (V), diversity (D), joining  (J),  and constant  (C) gene 
segments that encode both chains of the TCR. The homology 
of Vc~ and V~ sequences to those of VH and VL of Ig sug- 
gest that they might display a similar secondary and tertiary 
structure.  X-ray crystallographic  studies of Ig have  shown 
that V region domains on each chain form a series of loops 
that constitute complementarity determining regions (CDR) 1 
for antigen binding. Based on Ig structure, models for TCR- 
Ag-MHC recognition have been proposed in which the CDR3 
1 Abbreviations used in this paper: CDR,  complementarity determining 
region; EAE, experimental autoimmune encephalomyelitis;  Gp, guinea pig; 
m, mouse; MBP, myelin  basic protein; NZB, New Zealand black; NZW, 
New Zealand white. 
region interacts with the MHC-bound peptide and CDR1 
and CDR2 interact with the flanking MHC o~-helices (3-5). 
It has been shown that junctional CDR3 sequences correlate 
with peptide recognition in T  cells with similar specificity 
(6-10). Consistent with this model, mutations in conserved 
junctional residues result in altered recognition of I-Ek-cytC 
(11). R.ecently,  direct CDR3-peptide contact has been sug- 
gested in a transgenic model for cytochrome C recognition, 
where substitution of charged residues on the peptide elicited 
reciprocal charges in CDR3 sequences upon peptide immu- 
nization  (12). 
New Zealand white (NZW) mice have generated interest 
because of their role in the autoimmunity of New Zealand 
black (NZB  x  NZW)F1 hybrids, which display similar fea- 
tures to those observed in human systemic lupus erythematosus 
(SLE)  (13). The exact basis of their genetic contribution to 
the F1 disease is not yet understood. Both H-2-1inked (14-16) 
as well as TCR genes (17) and other non-MHC background 
genes have been suggested to be important in disease devel- 
opment.  Furthermore,  it is clear that  although  SLE is a B 
cell-mediated disease,  T  cells  are evidently involved at  the 
initial  stages of autoimmunity  (18,  19). 
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mice, originally tissue-typed as the unique haplotype, H-2  z, 
are actually identical to the respective genes of mice of the 
H-2  u haplotype, such as B10.PL and PL/J (20, 21). Initially, 
most myelin basic protein (MBP)-reactive T cells from B10.PL 
or  PL/J  mice  respond  to  the  immunodominant  NH2- 
terminal fragment Acl-9, and predominantly use the TCR 
V~8.2 gene segment (7, 8). Although, other V~/gene seg- 
ments (V~13 or V~4) are also used for the recognition of 
Acl-9-specific T  cells in both mouse strains,  all T cells that 
have been analyzed only used the same DE and J~/gene seg- 
ment cluster, D~/2-J~/2 (see Table  1).  Moreover, junctional 
amino acid residues across the third hypervariable region were 
conserved in spite of N-region variation at the nucleotide level 
(7, 22). Importantly, in spite of the different non-MHC genetic 
background in B10.PL and PL/J mice, TCR. V-gene segment 
usage was highly similar and restricted in the recognition 
of Acl-9/A  u. Since NZW mice also express identical MHC 
class II molecules, i.e.,  I-A  u and I-E  ~ (20, 21),  we were in- 
terested in analyzing the TCR-recognition pattern of Acl- 
9/A  u in this mouse strain because of its genomic deletion of 
an 8.8-kb segment of DNA containing the crucial D~/2 and 
Jfl2 gene segments (23). Although, the relative importance 
of these gene segments in antigen recognition has been demon- 
strated in congenic strains such as BALB/c and the congenic 
partner  BALB/c.V~/Nzw  that  bears  the  D~/2-J~2-deletion 
(24), responses to specific determinants whose recognition 
is biased towards the usage of DB2-Jfl2 gene segments have 
not been analyzed. Would NZW mice, in the absence of this 
gene cluster, be able to exploit an alternative gene segment 
in order to respond to Acl-9/A~? 
We therefore have asked whether the T  cell repertoire is 
highly constrained in its usage of the DB-JB2 region in the 
recognition of Acl-9.  We have shown that in the absence 
of genes coding for the appropriate CDR3 region, the NZW 
mouse simply fails to respond to this dominant determinant 
on MBP. Likewise, upon peptide immunization, NZW mice 
are almost nonresponsive to Acl-9/A  ~ and 31-50/E  u, whereas 
Table  1.  The D~2 and J~2 Gene Segments Are  Used for 
Recognition of Acl-9/A u Irrespective of the Non-MHC 
Background Genes 
Vfl gene  D~/-Jfl gene 
segments  segments  B10.PL mice  PL/J mice 
% 
8.2  2-2.6  79  50 
8.2  2-2.3  -  25 
8.2  2-2.5  -  12 
13  2-2.2  21  - 
4  2-2.5  -  12 
See references 7, 8, 22. 
response to other, subdominant/cryptic determinants of MBP, 
different determinants within Acl-20 and MBP 121-140/A u, 
remained unaffected. The loss of response to the dominant 
and  subdominant  self-determinants  has  important  conse- 
quences for self-tolerance and autoimmunity. 
Materials and Methods 
Mice.  B10.PL  and NZW mice were purchased  from The  Jackson 
Laboratory (Bar Harbor, ME), and bred under specific  pathogen- 
free conditions in our own colony. Female mice were used at 8-20 
wk of age. 
TCR Peptides.  Peptide  Acl-9 was synthesized  by C. Miles (Mac- 
romolecular  Resources, Fort  Collins, CO),  and  MBP Acl-20, 
MBP31-50, and  MBP121-140 were  synthesized by S.  Horvath 
(Caltech, Pasadena, CA) using a solid phase technique on a peptide 
synthesizer (model 430A; Applied Biosystems, Inc., Foster City, 
CA) and purified on a reversed  phase column by high performance 
liquid chromatography (25). 
Proliferation Assays.  For lymph node proliferation assays, mice 
were immunized subcutaneously with 7 nmol of the mMBP pep- 
tides or 100 #g of GpMBP, emulsified (1:1) in CFA (Difco Labora- 
tories, Detroit, MI). The draining popliteal and inguinal lymph 
nodes were removed 10 d after immunization and a single cell sus- 
pension was prepared. Lymph node cells (4  x  105 cells/well) were 
cultured in 96-well  microtiter plates in 200 #1 of serum-free  medium 
(HL-1; Ventrex Laboratories, Portland, ME) supplemented with 2 
mM glutamine; peptides were added at concentrations  ranging from 
0.1 to 7 #M, final concentration. Proliferation was assayed  by addi- 
tion of 1 #Ci [3H]thymidine  (International Chemical and Nuclear, 
Irvine, CA) for the last 18 h of a 5-day culture, and incorporation 
of label was measured by liquid scintillation counting. 
The antigen processing  and presentation capacity  of NZW APCs 
was determined by measuring antigen-specific  proliferation of the 
Acl-9-specific T cell clone, 2C6 (7). T cells (5  x  104-1 x  105 
cells/well) were incubated with irradiated spleen cells (1-5  x  105 
cells/well) in the presence of MBP or Acl-9 at different concentra- 
tions (1 nM to 14 #M). Proliferation of the T cell clone was mea- 
sured by [3H]thymidine incorporation for the last 18 h of a 3-day 
culture  as described above. 
Induction of Experimental Autoimmune Encephalomyelitis (EAE). 
MBP was isolated from the brains of guinea pigs (Pel-Freez  Bio- 
logicals, Rogers, AK) or mice as described (26). For induction of 
EAE, mice were immunized subcutaneously with 100 #g mMBP 
or its peptides in CFA. 0.1 #g pertussis toxin (List Biological  Labora- 
tories Inc., Campbell, CA) was injected in 200 #1 of saline, intrave- 
nously, 24 and 72 h later. Mice were observed daily for signs of 
EAE as previously described (27, 28) and until >60 d after MBP 
immunization. 
Flow Cytometry Analysis.  To  determine  the  expression of 
V~8.2 + T  cells, the following mAbs were used: anti-CD4-PE 
(GK1.5, Becton Dickinson & Co., Mountain View, CA) and anti- 
VBS.2 (F23.2) (29). F23.2 antibody was purified from hybridoma 
supernatants by protein A chromatography. Antibodies were used 
in PBS containing  1% fetal bovine serum.  106 splenocytes, after 
red blood cell lysis, were stained with 0.5 #g of antibody in a total 
volume of 50 #1 at 4~  for 30 rain. Cells were washed twice with 
PBS and then resuspended in  50 #1 of a 1:50 dilution  of goat 
anti-mouse FITC (Southern Biotechnology Associates, Birming- 
ham, AL). After 20 rain at 4~  cells were washed, fixed with 
1% paraformaldehyde  in PBS, and analyzed  using a cytofluorograph 
(Becton Dickinson  & Co.). 
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Figure  1.  The loss  of the domi- 
nant response  to MBP Acl-9/A  u in 
NZW mice. Proliferative responses of 
GpMBP-primed  lymph  node  cells 
from NZW (A) and B10.PL (B) mice 
were  recalled  in vitro with various 
concentrations (#M) of Acl-9 (O) or 
MBP (0). Responses from three in- 
dividual mice are shown. The data are 
expressed as arithmetic means _+ SD 
of  [3H]-thymidine  incorporation 
(cpm  x  10-3) in triplicate cultures. 
The  background  incorporation  in 
NZW  (A)  and  B10.PL  (B)  mice 
ranged  from  10,263  to  11,960 and 
1,372 to 2,480 cpm, respectively. This 
experiment is one representative  of 
three separate experiments. 
Results and Discussion 
MBP Does Not Induce the Dominant Acl-9-specific  T Cells. 
To determine the consequences for the dominance of response 
to Acl-9 in the absence of critical D/3-J~/genes,  both NZW 
(Fig. 1 A) and B10.PL (Fig. 1 B) mice were immunized with 
MBP and the T cell proliferative recall to MBP or Acl-9 was 
followed in the draining lymph nodes. Comparable responses 
to MBP were found in both mouse strains.  However, the 
proliferative recall to Acl-9, present in B10.PL mice, was ab- 
sent in NZW mice immunized with MBP (Fig.  1 A). This 
suggests that these animals either are nonresponsive to Acl-9, 
or they are able to respond to Acl-9, but in the absence of 
certain critical CDR3-bearing T  cells,  Acl-9 behaves  as a 
cryptic determinant and these T cells can not be recalled after 
MBP immunization (30). 
Peptide Immunization  Fails to Stimulate Acl-9/A"-specific  T 
Cells.  Proliferative responses  to Acl-9 were then tested in 
mice immunized with the peptide itself emulsified in CFA. 
Fig. 2 indicates that lymph node cells from NZW mice showed 
almost no proliferation to Acl-9 (stimulation indices <3), 
whereas peptide-reactive T cells were readily primed in B10.PL 
mice. Indeed, the primed T cells could be recalled with MBP 
in  B10.PL  mice,  indicating dominance of the  Acl-9/A  u- 
specific response.  Furthermore, immunization as well as in 
vitro recall with an almost 100-fold higher concentration (700 
nmol) of Acl-9 did not result in any significant increase in 
lymph node proliferation in NZW mice (Fig. 3 B; stimula- 
tion indices <3). These observations clearly demonstrate the 
absence of the T cell proliferative response to Acl-9 in NZW 
mice and further suggest an essential role for particular amino 
acid residues in the CDR3 region in the recognition of Acl- 
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9/A  u. Other T  cells, directed against a cryptic determinant 
within MBP Acl-20 (region 6-20 of MBP), remain unaffected 
as peptide-immunization resulted in a comparable prolifera- 
tive response  to that in B10.PL mice (Fig. 2). Similarly, re- 
,'? 
O 
x 
=E 
Q. 
o 
150 
120 
90 
60 
30 
=.  ￿9  ￿9 
t  ￿9  :  ! 
i  i  I  ￿9  I  I  | 
Acl-9N  Ar  B  ACl-20N  Ar  31-50.N  31-50B  121-140 N  121-140B 
PEPTIDE  IMMUNIZATIONS 
Figure 2.  NZW mice respond very poorly to the dominant Acl-9/A  u 
as well as to the subdominant 35-47/E  u. Groups of mice (N, NZW; B, 
B10.PL)  were immunized subcutaneously with 7 nmol of each peptide 
in CFA.  10 d later, lymph node proliferative responses to respective pep- 
tides were measured at varying concentrations of antigen. Response  of 
3-6 individual mice to each peptide at the optimal concentration of 7 #M 
is shown. Background incorporation with medium alone ranged from 658 
to 4,251 cpm. The data are expressed as arithmetic means of [3H]thymi- 
dine incorporation (cpm  x  10- ~) in triplicate cultures.  The proliferative 
recall responses to purified protein derivative in both B10.PL and NZW 
mice were comparable and ranged from 65,000 to 140,000 cpm. These 
data are representative of three separate experiments. sponses to other downstream determinants  of MBP remain 
unaltered (Kumar, V., K. Stellrecht,  M. Meyer, and E. Ser- 
carz,  manuscript  in preparation). 
The  Subdominant  31-50/E"-reactive  T  Cells  Fail  to  Be 
Primed by Peptide Immunization.  Interestingly, a proliferative 
response  to  the  subdominant  determinant  MBP 31-50/E u 
was also not detected after peptide immunization  (Fig.  2). 
As with Acl-9/A", challenge and in vitro recall at a 100-fold 
higher concentration (700 nmol) of MBP 31-50/E u did not 
show any proliferation (data not shown). It has been shown 
previously that T cells specific for MBP 35-47 (or 31-50) do 
not use Vfl8 gene segments (31). However, Dfl-Jfl gene seg- 
ments used by 31-50-reactive T cells have not been identified. 
The absence of a proliferative response to this subdominant 
determinant  of MBP in NZW mice is a strong indication 
that  31-50/ELspecific  T  cells  also  predominantly  express 
Dfl2 or Jfl2 gene segments. 
Response to the 121-140/A" Determinant Is Unaffected by the 
Absence of tile TCR D/82 or Jfl2 Gene Segments.  We then 
asked whether  the response to other  known  A"-restricted 
determinants  on MBP, for example MBP121-140 (32), was 
compromised due to deletion of the Dfl2-Jfl2 duster in NZW 
mice. Mice were immunized subcutaneously with MBP 121- 
140 and 10 d later, the proliferative response was checked in 
the draining lymph nodes (Fig.  2). All mice responded well 
to this subdominant/cryptic determinant when peptide was 
used for immunization.  Presumably, MBP121-140-reactive 
T  cells use other Dfl and Jfl genes and therefore, response 
to this determinant  was not  affected. 
Failure to Respond to Aci-9 Is Not Linked to the Peripheral 
ExFession of the VflS.2 Gene Segment.  To determine whether 
there  might  be  an  overall  decrease in  VflS.2 +  T  cells  in 
NZW mice, we next examined their expression in peripheral 
T cells by flow cytometry. Actually, expression of the Vf18.2 
gene  segment  was  significantly  increased  in  NZW  mice 
(CD4+-Vfl8.2 +  --  9.8%)  compared  with  B10.PL  mice 
(CD4+-VflS.2 +  =  5%).  The  loss of the dominant  Acl- 
9/A  ~ response in  these mice is  therefore not due to lower 
expression of the Vf18.2 gene segment among mature T cells. 
APC from NZW  Mice Are Not Defective in Processing MBP 
or in Presenting Aci-9.  One possibility is that  NZW mice 
have an appropriate MHC molecule (A") as well as a T  cell 
repertoire capable of recognizing Acl-9, but a processing de- 
fect exists preventing formation of the Acl-9/A" complex. 
Several factors determine the binding of a given peptide in- 
cluding its availability after antigen processing. A processing 
defect resulting in genetic unresponsiveness to a hen egg lyso- 
zyme determinant by failure to remove a single amino acid 
hindering peptide binding to MHC has recently been shown 
(Grewal, I., K. Moudgil, E. E. Sercarz, manuscript submitted 
for publication). Accordingly,  we tested whether NZW splenic 
APC pulsed with MBP or Acl-9 were able to stimulate an 
Acl-9-specific T  cell clone derived from B10.PL mice. Fig. 
4 clearly demonstrates that APCs from NZW mice were able 
to present Acl-9 to specific T cells in vitro. Also, since NZW 
APCs were able to stimulate Acl-9-reactive T  cells  when 
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Figure  3.  Challenge of NZW mice with increased antigenic dose does 
not overcome proliferative unresponsiveness to Acl-9. Both B10.PL (A) 
and NZW (B) mice were immunized with Acl-9 (700 nmol)  in CFA. 
10 d later, lymph node proliferative responses to various concentrations 
(#M) of the antigen were recalled in vitro,  as in Fig. 1. Responses from 
four individual mice are shown. The data are expressed as arithmetic means 
-+  SD of [3H]thymidine  incorporation (cpm  x  10-3)  in triplicate  cul- 
tures. This experiment  is one representative of two separate experiments. 
pulsed with whole MBP, there seemed to be no defect evi- 
dent in antigen processing. 
Peptide Immunization Also Fails to Induce a Significant Inci- 
dence of  EAE.  The poor proliferative responses to Acl-9 and 
31-50 in NZW mice shown by in vitro assays were further 
confirmed by monitoring induction of Acl-9 or 31-50-induced 
EAE as a measure of in vivo response.  Table 2  shows that 
the incidence of disease is extremely low when mice were 
1640  UnresponsivenesS to the Dominant and Subdominant  Self 100 
80 
",  60 
0 
x 
z 
el 
o  40 
20 
0 
Medium  MBP  Aci-9 
Figure  4.  NZW splenic APCs are able to process MBP and present 
Acl-9. MBP or Acl-9-specific  proliferation  of clone 2C6, derived  from 
B10.PL mice  after  challenge  with MBP (7), was measured  in the presence 
of irradiated splenic cells from NZW (m) or B10.PL  ([~) mice. 3H-Incor- 
poration in response to an optimum concentration  of antigen (7 #M) is 
shown. The data are expressed  as arithmetic mean _+ SD of [3H]thymi- 
dine incorporation (cpm  x  10-3) in triplicate cultures. Clone 2C6 is 
specific for Acl-9 and does not recognize  any of the other determinants 
of MBP, for example, MBP 31-50, 121-140, or 131-150. 
injected with either of these two determinants with adju- 
vant and pertussis toxin. However, immunization with whole 
MBP as well as with other determinants, Acl-20 and MBP 
121-140, resulted in a significant incidence of EAE in NZW 
Table  2.  Susceptibility  of BIO.PL and NZW Mice to 
EAE Induction with the Dominant or the Subdominant 
Determinant of MBP 
Antigen  B10.PL mice  NZW mice 
MBP  8/11  6/12 
Acl-9 (Expt.  1)  8/10  1/13" 
Acl-9 (Expt.  2)  5/5  0/5 
Acl-20  5/5  4/5 
MBP 121-140  4/5  3/5 
MBP 31-50 (Expt.  1)  6/10  0/9 
MBP 31-50 (Expt.  2)  3/5  0/5 
* A single mouse appeared to have  developed  transient tail paralysis (for 
3 d) after almost 30 d. Although the severity of EAE in both mouse 
strains induced with mMBP as well as with Acl-20 and 121-140 was 
comparable, the onset of disease was 5-8 d later in NZW mice (15-20 d 
after antigenic challange). 
mice, although, the onset of disease in NZW mice was later 
(19-21 d) than in B10.PL mice (10-13 d) after antigenic chal- 
lenge. Thus, disease induction with whole MBP in NZW 
mice must be due to the presence of other dominant and cryptic 
encephalitogenic determinants on MBP,  for example,  121- 
140 (Kumar, V., K. Stellrecht, M. Meyer, and E. E. Sercarz, 
manuscript in preparation). Similar findings regarding the 
induction of EAE with Ac1-11 and 35-47 have recently been 
reported (33). 
Absence of Critical Residues within CDR3 Constrains T Cell 
Recognition Specificity.  These data demonstrate constraints 
in the recognition of certain antigenic structures in spite of 
the myriad possibilities for TCP, diversity. Presumably, the 
lack of particular dominant T cells with high avidity TCRs 
results in nonresponsiveness even to strong antigenic deter- 
minants, or "holes in the repertoire." Genetic unresponsive- 
ness to protein antigens has generally been attributed to three 
different mechanisms: the failure to bind to MHC molecules 
(34-36); or to holes in the T  cell repertoire, even when the 
peptide binds to MHC (37, 38); or to regulatory effects (39). 
The absence  of an appropriate T  cell repertoire capable of 
recognizing the antigen has been attributed primarily to clonal 
deletion during thymic tolerance induction (40) or to periph- 
eral clonal exhaustion (41) after a vigorous response. It has 
been previously demonstrated that the germline deletion of 
appropriate V/3 gene segments compromises the immune re- 
sponsiveness  to certain antigens (42). In these studies, chi- 
meric  mice with  a  truncated  V~8  ~ repertoire missing  the 
TCR V~88 and Vj813 gene segments  and expressing H-2  u 
MHC genes were unable to devise a response to Acl-9/A  u. 
Here, we have demonstrated that the lack of appropriate genes 
within the CDR3 region results in the loss of a proliferative 
response to a dominant and a subdominant self-determinant, 
probably owing to the absence of high avidity TCRs capable 
of recognizing the MBP Acl-9/A  u or the 31-50/E  u com- 
plexes,  respectively. 
As  in  the  comparison  of the  response  to  Acl-9/A  u in 
B10.PL and PL/J mice, it has been shown that remarkably 
similar junctional sequences among TCR/3 chains are em- 
ployed to respond to a given determinant of sperm whale 
myoglobin by animals that differ in their non-MHC back- 
ground genes, including Mls (43). Thus, the lack of response 
to Acl-9 in NZW mice suggests that the TCP, structures 
capable of recognizing this determinant are similar with re- 
spect to the usage of DB-J~ gene segments in all three H-2  u 
haplotypes. Although the presence of extremely low affinity/ 
frequency T  cells  of Acl-9/A  u or  35-47/Eu-specificity in 
NZW mice cannot be ruled out, their activity is not detect- 
able with in vitro or in vivo assays. It is possible that low 
affinity T  cells specific for these determinants still exist and 
are of the Th2 type. These cells usually do not proliferate 
well and are likely to be poorly encephalitogenic. Thus, holes 
in the repertoire exist, probably due to the absence of TCP,  s 
employing appropriate D~-J~ gene segments. It seems that 
the interaction between the TCR structures and their ligands, 
Acl-9/A  u or 31-50/E  ~ complexes, is stringent enough to de- 
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residues in the CDR3 region (D/32-JB2),  despite the avail- 
ability of closely related gene segments within the DB1-J~I 
region. These data favor proposed models of TCK recogni- 
tion (4,  5,  12) that stress  involvement of the region in the 
neighborhood of the V,  (D), and J junctions of the ot and 
TCR chains in constituting the antigenic peptide-specific 
sites  on the TCR molecule. 
We would like to suggest a hypothesis that NZW genes 
have  two  functions  in  promoting  autoimmunity  in  the 
(NZB  x  NZW)F1  mouse.  First,  they provide the  H-2  u 
haplotype which permits immune responsiveness to certain 
self-determinants;  second,  they mediate autoimmunity by 
failing to provide an adequate regulatory repertoire. The de- 
letion of D/32  and JB2 gene segments in NZW mice may 
not only affect the emergence of effector T cells, for example, 
specific for Acl-9/A  u, but may also affect the appearance  of 
a regulatory T cell repertoire in the F1. In this connection, 
it  is  intriguing  that  (NZB  x  B10.PL)F1  or  (NZB  x 
PL/J)F1 do not develop characteristic anti-DNA antibodies. 
The lack of this protective regulatory T  cell subset (for ex- 
ample, in reference 44) could result in the loss of peripheral 
tolerance to a self-antigen, leading to autoimmunity (28, 45). 
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